| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrophoresis, Gel, Two-Dimensional | 6 | 2016 | 212 | 1.090 |
Why?
|
| Pattern Recognition, Automated | 3 | 2012 | 125 | 0.940 |
Why?
|
| Proteomics | 7 | 2016 | 1380 | 0.850 |
Why?
|
| Proteins | 5 | 2016 | 1963 | 0.760 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 8 | 2010 | 208 | 0.750 |
Why?
|
| Bayes Theorem | 5 | 2012 | 1021 | 0.670 |
Why?
|
| Algorithms | 11 | 2012 | 3890 | 0.620 |
Why?
|
| Arachidonate 15-Lipoxygenase | 9 | 2012 | 90 | 0.610 |
Why?
|
| Software | 5 | 2016 | 1321 | 0.580 |
Why?
|
| Models, Statistical | 5 | 2012 | 1171 | 0.580 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2015 | 2027 | 0.520 |
Why?
|
| Proteome | 7 | 2010 | 561 | 0.510 |
Why?
|
| Gene Expression Profiling | 8 | 2014 | 5159 | 0.450 |
Why?
|
| Colonic Neoplasms | 11 | 2012 | 1390 | 0.430 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2016 | 1648 | 0.410 |
Why?
|
| Liver Neoplasms | 9 | 2015 | 4557 | 0.400 |
Why?
|
| Peptide Mapping | 2 | 2007 | 114 | 0.380 |
Why?
|
| Models, Chemical | 2 | 2007 | 186 | 0.360 |
Why?
|
| Colorectal Neoplasms | 16 | 2013 | 3578 | 0.350 |
Why?
|
| Carcinogens | 6 | 2012 | 384 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2013 | 1533 | 0.330 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 630 | 0.320 |
Why?
|
| Sequence Analysis, Protein | 2 | 2007 | 81 | 0.320 |
Why?
|
| Data Interpretation, Statistical | 3 | 2010 | 482 | 0.300 |
Why?
|
| Colon | 5 | 2012 | 670 | 0.300 |
Why?
|
| DNA Adducts | 3 | 2003 | 210 | 0.260 |
Why?
|
| Models, Genetic | 2 | 2006 | 1113 | 0.250 |
Why?
|
| Biomarkers, Tumor | 6 | 2011 | 10331 | 0.240 |
Why?
|
| Adenocarcinoma | 14 | 2013 | 7789 | 0.240 |
Why?
|
| Artifacts | 2 | 2006 | 532 | 0.240 |
Why?
|
| Neoplasm Staging | 11 | 2011 | 13658 | 0.230 |
Why?
|
| Blood Proteins | 4 | 2005 | 294 | 0.220 |
Why?
|
| Reproducibility of Results | 10 | 2010 | 6009 | 0.220 |
Why?
|
| Esophageal Neoplasms | 7 | 2007 | 3168 | 0.220 |
Why?
|
| Computer Simulation | 4 | 2012 | 1529 | 0.220 |
Why?
|
| Mass Spectrometry | 6 | 2010 | 702 | 0.200 |
Why?
|
| Body Mass Index | 5 | 2015 | 2203 | 0.200 |
Why?
|
| Computational Biology | 1 | 2008 | 1271 | 0.200 |
Why?
|
| Deoxycytidine | 6 | 2011 | 1353 | 0.190 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 2508 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 5 | 2011 | 5061 | 0.180 |
Why?
|
| Environment Design | 2 | 2009 | 25 | 0.160 |
Why?
|
| Aged | 39 | 2015 | 70117 | 0.160 |
Why?
|
| Diet | 3 | 2003 | 1440 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2012 | 15862 | 0.160 |
Why?
|
| Middle Aged | 42 | 2015 | 86204 | 0.160 |
Why?
|
| Fluorouracil | 8 | 2010 | 1944 | 0.160 |
Why?
|
| Male | 52 | 2015 | 123000 | 0.160 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2010 | 209 | 0.150 |
Why?
|
| CpG Islands | 3 | 2008 | 633 | 0.150 |
Why?
|
| Female | 55 | 2015 | 141928 | 0.150 |
Why?
|
| Neoplasm Proteins | 2 | 2008 | 3230 | 0.150 |
Why?
|
| Humans | 71 | 2015 | 261506 | 0.140 |
Why?
|
| Intestinal Mucosa | 6 | 2012 | 1081 | 0.140 |
Why?
|
| Azoxymethane | 4 | 2012 | 43 | 0.140 |
Why?
|
| Apoptosis | 10 | 2008 | 7591 | 0.140 |
Why?
|
| Obesity | 4 | 2015 | 2884 | 0.130 |
Why?
|
| Quinazolines | 3 | 2012 | 923 | 0.130 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2014 | 21 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2012 | 6150 | 0.130 |
Why?
|
| Saccades | 1 | 2014 | 20 | 0.130 |
Why?
|
| Motor Activity | 2 | 2009 | 693 | 0.120 |
Why?
|
| Herpesvirus 8, Human | 1 | 2014 | 102 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2008 | 837 | 0.120 |
Why?
|
| DNA Methylation | 5 | 2008 | 2669 | 0.120 |
Why?
|
| Esophagoscopy | 2 | 2007 | 291 | 0.120 |
Why?
|
| Models, Biological | 4 | 2010 | 3254 | 0.120 |
Why?
|
| Tics | 1 | 2014 | 48 | 0.120 |
Why?
|
| Linoleic Acids | 4 | 2010 | 32 | 0.110 |
Why?
|
| Executive Function | 1 | 2014 | 160 | 0.110 |
Why?
|
| Stomach Neoplasms | 4 | 2007 | 2278 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2013 | 2330 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 160 | 0.110 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2003 | 83 | 0.110 |
Why?
|
| Sarcoma, Kaposi | 1 | 2014 | 187 | 0.110 |
Why?
|
| Sensitivity and Specificity | 6 | 2010 | 4971 | 0.110 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2004 | 177 | 0.110 |
Why?
|
| Tourette Syndrome | 1 | 2014 | 130 | 0.110 |
Why?
|
| Adult | 27 | 2015 | 77950 | 0.110 |
Why?
|
| Genes, Overlapping | 1 | 2011 | 13 | 0.110 |
Why?
|
| Barrett Esophagus | 2 | 2009 | 569 | 0.100 |
Why?
|
| Prognosis | 11 | 2011 | 21713 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2008 | 2063 | 0.100 |
Why?
|
| Sulfonamides | 6 | 2013 | 1823 | 0.100 |
Why?
|
| Fish Oils | 2 | 2003 | 88 | 0.100 |
Why?
|
| Lasers | 2 | 2010 | 198 | 0.100 |
Why?
|
| Esophagogastric Junction | 2 | 2005 | 543 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2013 | 3251 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 244 | 0.100 |
Why?
|
| Rectal Neoplasms | 3 | 2009 | 1202 | 0.100 |
Why?
|
| Aging | 2 | 2015 | 1582 | 0.100 |
Why?
|
| Selection, Genetic | 1 | 2011 | 189 | 0.100 |
Why?
|
| Appendiceal Neoplasms | 1 | 2013 | 234 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2014 | 399 | 0.100 |
Why?
|
| DNA Modification Methylases | 2 | 2008 | 172 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2004 | 521 | 0.100 |
Why?
|
| Lipoxygenase | 1 | 2010 | 24 | 0.100 |
Why?
|
| Risk | 3 | 2010 | 1972 | 0.090 |
Why?
|
| Influenza A virus | 1 | 2011 | 270 | 0.090 |
Why?
|
| Viruses | 1 | 2011 | 159 | 0.090 |
Why?
|
| alpha-Fetoproteins | 1 | 2011 | 237 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2011 | 6207 | 0.090 |
Why?
|
| Transgenes | 1 | 2012 | 557 | 0.090 |
Why?
|
| Protein Array Analysis | 4 | 2005 | 501 | 0.090 |
Why?
|
| Celecoxib | 5 | 2013 | 200 | 0.090 |
Why?
|
| DNA Repair | 4 | 2009 | 1872 | 0.090 |
Why?
|
| Capecitabine | 5 | 2010 | 388 | 0.090 |
Why?
|
| Particulate Matter | 1 | 2010 | 86 | 0.090 |
Why?
|
| Viral Proteins | 1 | 2011 | 435 | 0.080 |
Why?
|
| Sepsis | 1 | 2014 | 652 | 0.080 |
Why?
|
| Embolization, Therapeutic | 2 | 2005 | 551 | 0.080 |
Why?
|
| Air Pollution | 1 | 2010 | 87 | 0.080 |
Why?
|
| Carcinoma | 3 | 2006 | 2578 | 0.080 |
Why?
|
| Risk Factors | 5 | 2015 | 17523 | 0.080 |
Why?
|
| Genes, APC | 1 | 2008 | 70 | 0.080 |
Why?
|
| Architecture | 1 | 2007 | 2 | 0.080 |
Why?
|
| Databases, Protein | 2 | 2006 | 100 | 0.080 |
Why?
|
| Bevacizumab | 4 | 2013 | 938 | 0.080 |
Why?
|
| Body Fluids | 2 | 2005 | 125 | 0.080 |
Why?
|
| Quality Control | 2 | 2006 | 457 | 0.080 |
Why?
|
| Endosonography | 3 | 2007 | 536 | 0.080 |
Why?
|
| Hepatectomy | 2 | 2005 | 1011 | 0.080 |
Why?
|
| Case-Control Studies | 6 | 2015 | 6100 | 0.070 |
Why?
|
| Mammography | 1 | 2013 | 1010 | 0.070 |
Why?
|
| Rats | 6 | 2008 | 6086 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 761 | 0.070 |
Why?
|
| GATA6 Transcription Factor | 1 | 2006 | 23 | 0.070 |
Why?
|
| Polyvinyl Alcohol | 2 | 2005 | 19 | 0.070 |
Why?
|
| Combined Modality Therapy | 10 | 2009 | 8865 | 0.070 |
Why?
|
| Hernia, Hiatal | 1 | 2007 | 63 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2008 | 237 | 0.070 |
Why?
|
| Linear Models | 1 | 2010 | 1085 | 0.070 |
Why?
|
| Intestinal Neoplasms | 1 | 2008 | 189 | 0.070 |
Why?
|
| Computer Graphics | 1 | 2006 | 82 | 0.070 |
Why?
|
| Nipples | 2 | 2005 | 132 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2013 | 8873 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2009 | 348 | 0.070 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 365 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 1299 | 0.070 |
Why?
|
| PPAR-beta | 1 | 2006 | 14 | 0.070 |
Why?
|
| Linoleic Acid | 1 | 2006 | 29 | 0.070 |
Why?
|
| Preoperative Care | 4 | 2007 | 1529 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2013 | 1283 | 0.070 |
Why?
|
| Gene Library | 2 | 2004 | 294 | 0.070 |
Why?
|
| Morphine | 1 | 2008 | 308 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2009 | 2967 | 0.070 |
Why?
|
| Camptothecin | 2 | 2009 | 517 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 4988 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 4298 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 135 | 0.070 |
Why?
|
| Radiotherapy | 4 | 2007 | 1824 | 0.070 |
Why?
|
| Paraparesis, Tropical Spastic | 1 | 2005 | 7 | 0.070 |
Why?
|
| Intestinal Polyps | 2 | 2005 | 72 | 0.070 |
Why?
|
| Esophagectomy | 3 | 2005 | 911 | 0.070 |
Why?
|
| Schools | 1 | 2007 | 233 | 0.070 |
Why?
|
| Overweight | 1 | 2009 | 484 | 0.070 |
Why?
|
| PPAR delta | 1 | 2006 | 55 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2010 | 607 | 0.070 |
Why?
|
| Complex Mixtures | 1 | 2005 | 3 | 0.070 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2008 | 310 | 0.070 |
Why?
|
| Portal Vein | 2 | 2005 | 355 | 0.070 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2005 | 65 | 0.070 |
Why?
|
| Intestinal Polyposis | 1 | 2005 | 30 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2008 | 499 | 0.060 |
Why?
|
| Biomedical Engineering | 1 | 2005 | 45 | 0.060 |
Why?
|
| Biotechnology | 1 | 2005 | 63 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2006 | 286 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2006 | 229 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2232 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 4892 | 0.060 |
Why?
|
| Students | 1 | 2007 | 324 | 0.060 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 118 | 0.060 |
Why?
|
| Aged, 80 and over | 14 | 2012 | 29902 | 0.060 |
Why?
|
| Mammary Glands, Human | 1 | 2005 | 184 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 363 | 0.060 |
Why?
|
| Disease-Free Survival | 7 | 2013 | 10001 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 1070 | 0.060 |
Why?
|
| Ovarian Neoplasms | 3 | 2005 | 4638 | 0.060 |
Why?
|
| Gene Expression | 2 | 2010 | 3570 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2011 | 925 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2011 | 4844 | 0.060 |
Why?
|
| Erlotinib Hydrochloride | 3 | 2012 | 388 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2006 | 2074 | 0.060 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 101 | 0.060 |
Why?
|
| Artificial Intelligence | 1 | 2007 | 388 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3981 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1450 | 0.060 |
Why?
|
| Chromatin | 1 | 2008 | 942 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2006 | 3890 | 0.060 |
Why?
|
| Adenoma | 3 | 2005 | 716 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 6089 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2006 | 393 | 0.060 |
Why?
|
| Health Behavior | 1 | 2007 | 603 | 0.050 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2004 | 221 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2005 | 2231 | 0.050 |
Why?
|
| Research Design | 3 | 2005 | 1544 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 164 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2003 | 166 | 0.050 |
Why?
|
| Scalp | 1 | 2003 | 156 | 0.050 |
Why?
|
| ErbB Receptors | 4 | 2013 | 2295 | 0.050 |
Why?
|
| Survival Analysis | 6 | 2014 | 9180 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2002 | 614 | 0.050 |
Why?
|
| Biometry | 1 | 2003 | 241 | 0.050 |
Why?
|
| Prodrugs | 1 | 2002 | 217 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 4233 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2947 | 0.050 |
Why?
|
| Pyrazoles | 5 | 2013 | 1471 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2011 | 6869 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 4 | 2009 | 3101 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2009 | 1664 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2005 | 1996 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2003 | 234 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 1399 | 0.050 |
Why?
|
| Gallbladder Neoplasms | 1 | 2003 | 245 | 0.050 |
Why?
|
| Biomarkers | 2 | 2010 | 5047 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2009 | 14551 | 0.050 |
Why?
|
| Age of Onset | 2 | 2015 | 827 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2008 | 1616 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2013 | 4367 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 1823 | 0.050 |
Why?
|
| Comorbidity | 3 | 2014 | 2352 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2004 | 1910 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5178 | 0.040 |
Why?
|
| Animals | 12 | 2012 | 59536 | 0.040 |
Why?
|
| Colonic Polyps | 1 | 2002 | 209 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2009 | 2086 | 0.040 |
Why?
|
| Treatment Outcome | 10 | 2013 | 32848 | 0.040 |
Why?
|
| Retrospective Studies | 9 | 2013 | 37905 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 1011 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 591 | 0.040 |
Why?
|
| DNA Damage | 3 | 2001 | 1954 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2000 | 396 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 582 | 0.040 |
Why?
|
| Cadherins | 1 | 2001 | 660 | 0.040 |
Why?
|
| Mutation | 5 | 2013 | 15179 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 1 | 2000 | 362 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2003 | 620 | 0.040 |
Why?
|
| Organoplatinum Compounds | 2 | 2011 | 702 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2001 | 627 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 3 | 2005 | 4975 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2013 | 5112 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 2 | 2013 | 483 | 0.040 |
Why?
|
| Breast Neoplasms | 4 | 2005 | 15694 | 0.040 |
Why?
|
| ras Proteins | 2 | 2013 | 770 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 1688 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 1033 | 0.030 |
Why?
|
| Phylogeny | 2 | 2011 | 826 | 0.030 |
Why?
|
| Up-Regulation | 3 | 2012 | 2450 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2009 | 14289 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 2483 | 0.030 |
Why?
|
| Adolescent | 7 | 2014 | 31252 | 0.030 |
Why?
|
| Liver | 1 | 2005 | 2961 | 0.030 |
Why?
|
| APACHE | 1 | 2014 | 93 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2012 | 703 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2013 | 1331 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 193 | 0.030 |
Why?
|
| Analysis of Variance | 3 | 2004 | 2307 | 0.030 |
Why?
|
| Age Distribution | 2 | 2009 | 698 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2009 | 1546 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 1586 | 0.030 |
Why?
|
| Likelihood Functions | 2 | 2007 | 233 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2013 | 54 | 0.030 |
Why?
|
| Southwestern United States | 1 | 2013 | 62 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2010 | 5319 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2008 | 1519 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2014 | 519 | 0.030 |
Why?
|
| Reading Frames | 1 | 2011 | 6 | 0.030 |
Why?
|
| Angiopoietin-2 | 1 | 2012 | 38 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 2488 | 0.030 |
Why?
|
| Cetuximab | 1 | 2013 | 472 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 709 | 0.030 |
Why?
|
| Genes, p16 | 2 | 2002 | 125 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 400 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2008 | 1459 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 4320 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2012 | 261 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2011 | 155 | 0.020 |
Why?
|
| Survival Rate | 4 | 2005 | 12221 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 995 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2004 | 1165 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2006 | 1544 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 886 | 0.020 |
Why?
|
| Informatics | 1 | 2010 | 21 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 3472 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 3154 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2014 | 1038 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 3869 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2009 | 17 | 0.020 |
Why?
|
| Boston | 1 | 2009 | 108 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 342 | 0.020 |
Why?
|
| Histone Deacetylase 2 | 1 | 2009 | 35 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2003 | 5270 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2009 | 62 | 0.020 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2009 | 28 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 4053 | 0.020 |
Why?
|
| Disease Progression | 2 | 2013 | 6682 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 300 | 0.020 |
Why?
|
| Logistic Models | 2 | 2007 | 3441 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2007 | 7548 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 684 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2008 | 131 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2013 | 2819 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2009 | 4314 | 0.020 |
Why?
|
| STAT6 Transcription Factor | 1 | 2008 | 67 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 1217 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2003 | 3976 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2003 | 5542 | 0.020 |
Why?
|
| Mice | 5 | 2012 | 34495 | 0.020 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2008 | 83 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2008 | 206 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1945 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2008 | 119 | 0.020 |
Why?
|
| Remission Induction | 2 | 2004 | 3569 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2008 | 196 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2006 | 5395 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2010 | 11538 | 0.020 |
Why?
|
| Base Sequence | 2 | 2005 | 4917 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 495 | 0.020 |
Why?
|
| Genes, cdc | 1 | 2007 | 81 | 0.020 |
Why?
|
| Yeasts | 1 | 2007 | 74 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 508 | 0.020 |
Why?
|
| Walking | 1 | 2009 | 277 | 0.020 |
Why?
|
| Precancerous Conditions | 2 | 2007 | 1058 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 4654 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 1678 | 0.020 |
Why?
|
| Cisplatin | 2 | 2004 | 2432 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2008 | 471 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2006 | 63 | 0.020 |
Why?
|
| Homozygote | 1 | 2009 | 717 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2006 | 158 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2007 | 205 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1538 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 2010 | 613 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 502 | 0.020 |
Why?
|
| Pathology, Surgical | 1 | 2006 | 81 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2008 | 397 | 0.020 |
Why?
|
| Neoplasms | 2 | 2010 | 15193 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 402 | 0.020 |
Why?
|
| Cell Division | 2 | 2000 | 2489 | 0.020 |
Why?
|
| Metaplasia | 1 | 2007 | 383 | 0.020 |
Why?
|
| Exanthema | 1 | 2007 | 211 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2004 | 22 | 0.020 |
Why?
|
| Gelatin | 1 | 2005 | 49 | 0.020 |
Why?
|
| Acrylic Resins | 1 | 2005 | 43 | 0.020 |
Why?
|
| Genes, ras | 1 | 2008 | 667 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 1549 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2008 | 716 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 612 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 1818 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2007 | 598 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2005 | 162 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 1053 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2009 | 652 | 0.020 |
Why?
|
| Microspheres | 1 | 2005 | 210 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 9244 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 133 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 4143 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 717 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2007 | 334 | 0.010 |
Why?
|
| Bias | 1 | 2004 | 205 | 0.010 |
Why?
|
| Calibration | 1 | 2005 | 337 | 0.010 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 353 | 0.010 |
Why?
|
| DNA | 2 | 2004 | 2693 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 2003 | 48 | 0.010 |
Why?
|
| Young Adult | 2 | 2015 | 21445 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2008 | 1090 | 0.010 |
Why?
|
| Diarrhea | 1 | 2007 | 686 | 0.010 |
Why?
|
| Leucovorin | 1 | 2004 | 332 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2007 | 518 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2005 | 5437 | 0.010 |
Why?
|
| Suction | 1 | 2003 | 104 | 0.010 |
Why?
|
| Esophagus | 1 | 2007 | 553 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 703 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 437 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2008 | 10035 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2004 | 208 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 2315 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 465 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2359 | 0.010 |
Why?
|
| Reference Standards | 1 | 2003 | 339 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2009 | 1555 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 2216 | 0.010 |
Why?
|
| Biopsy | 1 | 2010 | 3443 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2004 | 666 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 215 | 0.010 |
Why?
|
| Ionomycin | 1 | 2001 | 34 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2014 | 11965 | 0.010 |
Why?
|
| Folic Acid | 1 | 2004 | 349 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2002 | 200 | 0.010 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2001 | 69 | 0.010 |
Why?
|
| Nitrobenzenes | 1 | 2001 | 30 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 752 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 1439 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1363 | 0.010 |
Why?
|
| Sulindac | 1 | 2001 | 51 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 226 | 0.010 |
Why?
|
| Gastrectomy | 1 | 2004 | 451 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2003 | 6942 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 249 | 0.010 |
Why?
|
| Histones | 1 | 2008 | 1466 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 1082 | 0.010 |
Why?
|
| Fatigue | 1 | 2007 | 1239 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 1904 | 0.010 |
Why?
|
| Corn Oil | 1 | 2000 | 15 | 0.010 |
Why?
|
| tRNA Methyltransferases | 1 | 2000 | 15 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2001 | 284 | 0.010 |
Why?
|
| Pectins | 1 | 2000 | 10 | 0.010 |
Why?
|
| Cellulose | 1 | 2000 | 22 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 771 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 2001 | 202 | 0.010 |
Why?
|
| Protein Kinase C beta | 1 | 2000 | 35 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2001 | 314 | 0.010 |
Why?
|
| Genotype | 1 | 2009 | 4109 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2002 | 557 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2000 | 201 | 0.010 |
Why?
|
| Alkylation | 1 | 1999 | 29 | 0.010 |
Why?
|
| Methylation | 1 | 2001 | 597 | 0.010 |
Why?
|
| Guanine | 1 | 2000 | 151 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1999 | 76 | 0.010 |
Why?
|
| Hypoxia | 1 | 2002 | 443 | 0.010 |
Why?
|
| Bile Duct Neoplasms | 1 | 2005 | 493 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 3260 | 0.010 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 1999 | 87 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 1351 | 0.010 |
Why?
|
| Spleen | 1 | 2001 | 676 | 0.010 |
Why?
|
| Mass Screening | 1 | 2007 | 1509 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 7222 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 2292 | 0.010 |
Why?
|
| Child | 2 | 2014 | 29154 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 3842 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 5673 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2007 | 1225 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 2588 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 2944 | 0.010 |
Why?
|
| Smoking | 1 | 2007 | 2440 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 483 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 980 | 0.010 |
Why?
|
| Length of Stay | 1 | 2005 | 1900 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2001 | 842 | 0.010 |
Why?
|
| SEER Program | 1 | 2001 | 1000 | 0.010 |
Why?
|
| Pain | 1 | 2006 | 1658 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 862 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2005 | 806 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 4549 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 3343 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 3536 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 2173 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 3438 | 0.010 |
Why?
|
| Quality of Life | 1 | 2010 | 4532 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 4744 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 4307 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 1547 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 5687 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2000 | 2084 | 0.010 |
Why?
|
| Genomics | 1 | 2005 | 2738 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 1491 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2001 | 2022 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 7702 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 1350 | 0.010 |
Why?
|
| Stem Cells | 1 | 1999 | 1213 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 4757 | 0.010 |
Why?
|
| Age Factors | 1 | 2001 | 5377 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2006 | 12873 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1999 | 5637 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 6295 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 14889 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 12926 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 7551 | 0.000 |
Why?
|
| United States | 1 | 2001 | 15433 | 0.000 |
Why?
|